Physician profile
Hui Tang
NPI 1649275488
$1,651.79
in general payments reported to CMS, 2019-2025
23 companies · $277 in 2025
The $277 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $171 · 2023: $343 · 2024: $861 · 2025: $277.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,481.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,481.09 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $227.53 | 2022-2025 | Mounjaro, Zepbound |
| Novo Nordisk INC | $182.07 | 2023-2025 | Ozempic, Rybelsus, Wegovy |
| Inspire Medical Systems, INC. | $158.46 | 2023-2024 | Inspire |
| Exact Sciences Corporation | $141.72 | 2023-2025 | Cologuard Collection Kit |
| Abiomed | $128.95 | 2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $120.23 | 2024-2025 | |
| Amgen INC. | $101.01 | 2023-2024 | Prolia, Evenity |
| Corcept Therapeutics | $68.78 | 2025 | Korlym |
| Pfizer INC. | $67.12 | 2023-2024 | |
| Idorsia Pharmaceuticals US INC | $56.15 | 2023 | Quviviq |
| Sanofi-Aventis U.S. LLC | $54.89 | 2024-2025 | |
| Astellas Pharma US INC | $48.82 | 2023-2024 | Veozah |
| Glaxosmithkline, LLC. | $42.53 | 2024 | Trelegy Ellipta, Shingrix, Arexvy |
| Abbott Laboratories | $39.53 | 2023-2024 | Freestyle Libre 3, Eterna |
| Medtronic, INC. | $32.16 | 2024 | Intellis Adaptivestim, Venaseal |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Radius Health, INC. | $30.29 | 2025 | Tymlos |
| Astrazeneca Pharmaceuticals LP | $25.10 | 2024 | Farxiga |
| Noven Therapeutics, LLC | $24.90 | 2024 | Xelstrym |
| Horizon Therapeutics Plc | $23.38 | 2022 | |
| Gilead Sciences, INC. | $21.50 | 2024 | |
| Philips North America LLC | $20.88 | 2024 | (Ck7) Extended Holter |
| Cequr Corporation | $18.72 | 2024 | Cequr Simplicity |
| Boehringer Ingelheim Pharmaceuticals, INC. | $17.07 | 2023 | Jardiance |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Hui Tang listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.